|
1
|
Guarneri V and Conte PF: The curability of
breast cancer and the treatment of advanced disease. Eur J Nucl Med
Mol Imaging. 31:(Suppl 1). S149–S161. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gonzalez-Angulo AM, Morales-Vasquez F and
Hortobagyi GN: Overview of resistance to systemic therapy in
patients with breast cancer. Adv Exp Med Biol. 608:1–22. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cance WG, Carey LA, Calvo BF, Sartor C,
Sawyer L, Moore DT, Rosenman J, Ollila DW and Graham M: 2nd:
Long-term outcome of neoadjuvant therapy for locally advanced
breast carcinoma: Effective clinical downstaging allows breast
preservation and predicts outstanding local control and survival.
Ann Surg. 236:295–302; discussion 302–303. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
American Cancer Society, . Cancer Facts
& Figures 2014. American Cancer Society; Atlanta: 2014
|
|
5
|
Johnston SR: Enhancing endocrine therapy
for hormone receptor-positive advanced breast cancer: Cotargeting
signaling pathways. J Natl Cancer Inst. 107:djv2122015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Guarneri V, Miles D, Robert N, Diéras V,
Glaspy J, Smith I, Thomssen C, Biganzoli L, Taran T and Conte P:
Bevacizumab and osteonecrosis of the jaw: Incidence and association
with bisphosphonate therapy in three large prospective trials in
advanced breast cancer. Breast Cancer Res Treat. 122:181–188. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Watters AL, Hansen HJ, Williams T, Chou
JF, Riedel E, Halpern J, Tunick S, Bohle G, Huryn JM and Estilo CL:
Intravenous bisphosphonate-related osteonecrosis of the jaw:
Long-term follow-up of 109 patients. Oral Surg Oral Med Oral Pathol
Oral Radiol. 115:192–200. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Santos-Silva AR, Belizário Rosa GA, Castro
Júnior GD, Dias RB, Prado Ribeiro AC and Brandão TB: Osteonecrosis
of the mandible associated with bevacizumab therapy. Oral Surg Oral
Med Oral Pathol Oral Radiol. 115:e32–e36. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Christodoulou C, Pervena A, Klouvas G,
Galani E, Falagas ME, Tsakalos G, Visvikis A, Nikolakopoulou A,
Acholos V, Karapanagiotidis G, et al: Combination of
bisphosphonates and antiangiogenic factors induces osteonecrosis of
the jaw more frequently than bisphosphonates alone. Oncology.
76:209–211. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fleissig Y, Regev E and Lehman H:
Sunitinib related osteonecrosis of jaw: A case report. Oral
SurgOral Med Oral Pathol Oral Radiol. 113:e1–e3. 2012. View Article : Google Scholar
|
|
11
|
Marx RE: Pamidronate (Aredia) and
zoledronate (Zometa) induced avascular necrosis of the jaws: A
growing epidemic. J Oral Maxillofac Surg. 61:1115–1117. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Longato L, Cavalli L, Marcucci G, Metozzi
A, Giusti F, Brandi ML and Piscitelli P: Osteonecrosis of the jaw
in a patient with rheumatoid arthritis treated with an oral
aminobisphosphonate: A clinical case report. Clin Cases Miner Bone
Metab. 10:139–141. 2013.PubMed/NCBI
|
|
13
|
Giancola F, Campisi G, Lo Russo L, Muzio
LL and Di Fede O: Osteonecrosis of the jaw related to everolimus
and bisphosphonate: A unique case report? Ann Stomatol (Roma).
4:(Suppl 2). 20–21. 2013.PubMed/NCBI
|
|
14
|
Kim DW, Jung YS, Park HS and Jung HD:
Osteonecrosis of the jaw related to everolimus: A case report. Br J
Oral Maxillofac Surg. 51:e302–e304. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kneissel M, Luong-Nguyen NH, Baptist M,
Cortesi R, Zumstein-Mecker S, Kossida S, O'Reilly T, Lane H and
Susa M: Everolimus suppresses cancellous bone loss, bone
resorption, and cathepsin K expression by osteoclasts. Bone.
35:1144–1156. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Allegra A, Alonci A, Penna G, Granata A,
Siniscalchi E Nastro, Oteri G, Loddo S, Teti D, Cicciù D, De Ponte
FS and Musolino C: Bisphosphonates induce apoptosis of circulating
endothelial cells in multiple myeloma patients and in subjects with
bisphosphonate-induced osteonecrosis of the jaws. Acta Haematol.
124:79–85. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lane HA, Wood JM, McSheehy PM, Allegrini
PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM,
Martiny-Baron G, Schnell CR, et al: mTOR inhibitor RAD001
(everolimus) has antiangiogenic/vascular properties distinct from a
VEGFR tyrosine kinase inhibitor. Clin Cancer Res. 15:1612–1622.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yamashita J, McCauley LK and Van Poznak C:
Updates on osteonecrosis of the jaw. Curr Opin Support Palliat
Care. 4:200–206. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Troeltzsch M, Woodlock T, Kriegelstein S,
Steiner T, Messlinger K and Troeltzsch M: Physiology and
pharmacology of nonbisphosphonate drugs implicated in osteonecrosis
of the jaw. J Can Dent Assoc. 78:c852012.PubMed/NCBI
|
